Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M24D1 in advanced NSCLC and solid tumors
NCT07232420Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M24D1 in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
BL-M24D1
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07232420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232420.